All In Biotech

NDA 217188 · Pfizer

Paxlovid (Copackaged)

Nirmatrelvir, Ritonavir · Oral

NovelPriority review

CDER novel approval, May 25, 2023: To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19

Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

May 25, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

55

13 Phase 3, 11 recruiting

FAERS reports

53,956

9,681 serious, 563 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. FDA's summary: To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 31, 2025 Supplement 8 · Efficacy · priority review LabelLetter
  • May 25, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
2 products under this application
  • PAXLOVID (COPACKAGED) · NIRMATRELVIR 300MG; RITONAVIR 100MG · TABLET, ORAL · Prescription
  • PAXLOVID (COPACKAGED) · NIRMATRELVIR 150MG; RITONAVIR 100MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nirmatrelvir" as an intervention, any sponsor and status, largest first.

All 55 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service returned an error (500). The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 101 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.